PYXS

Pyxis Oncology, Inc. [PYXS] Stock Forecast

Q: What is Pyxis Oncology, Inc. stock symbol ?

Pyxis Oncology, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol PYXS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PYXS Stock Summary

Top 10 Correlated Stocks

PYXS

In the News

06:35 26 Mar 2023 PYXS

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates (ADCs) virtual conference. The pre-recorded presentation given by Lara Sullivan, M.D., President and Chief Executive Officer, and Jay Feingold, M.D., Ph.D., Chief Medical Officer, will be available on-demand at 9:00 a.m. ET on Wednesday, June 29, 2022.

06:35 26 Mar 2023 PYXS

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:

06:35 26 Mar 2023 PYXS

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tuesday, March 29, 2022 at 8:00 a.m. ET to discuss recent corporate updates.

08:00 26 Mar 2023 PYXS

Pyxis Oncology to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. A replay of the presentation will be available on the Events and Presentation page on Pyxis Oncology's website following the conference's conclusion.

PYXS Financial details

Company Rating

Neutral

Market Cap

91.89M

Income

-59.05M

Revenue

Book val./share

4.87

Cash/share

5.43

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

22 Mar 2023

P/E

-0.61

Forward P/E

PEG

0.08

P/S

P/B

0.38

P/C

0.41

P/FCF

-0.9

Quick Ratio

10.4

Current Ratio

10.62

Debt / Equity

0.31

LT Debt / Equity

0.12

EPS (TTM)

-1.82

EPS next Y

EPS next Q

EPS this Y

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

SMA20

16.4%

SMA50

54.93%

SMA100

22.91%

Inst Own

60.54%

Inst Trans

0.63%

ROA

-53%

ROE

-53%

ROC

-0.5%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

41.58M

Shs Float

Target Price

52W Range

1.1-5.0

52W High

-55.8%

52W Low

+121%

RSI

53.39

Rel Volume

7.06

Avg Volume

136.22K

Volume

961.88K

Perf Week

9.95%

Perf Month

45.39%

Perf Quarter

12.18%

Perf Half Y

11.62%

Beta

Volatility

0.24%, 0.31%

Prev Close

14.51%

Price

2.21

Change

3.76%

PYXS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0
Net income per share	-0.13	-0.58	-8.95	0
Operating cash flow per share	-0.1	-0.46	-4.16	-2.7
Free cash flow per share	-0.1	-0.53	-4.22	-2.9
Cash per share	0.9	0.37	32.35	5.43
Book value per share	-0.13	-0.71	30.77	4.87
Tangible book value per share	-0.13	-0.71	30.77	4.87
Share holders equity per share	-0.13	-0.71	30.77	4.87
Interest debt per share	0	0.04	0.02	0.57
Market cap	290.07M	290.07M	93.17M	44.26M
Enterprise value	270.4M	282.77M	-181.56M	-116.11M
P/E ratio	-104.64	-22.61	-1.23	0
Price to sales ratio	0	0	0	0
POCF ratio	-129.56	-28.77	-2.64	-0.5
PFCF ratio	-129.56	-25.08	-2.6	-0.46
P/B Ratio	-100.93	-18.54	0.36	0.28
PTB ratio	-100.93	-18.54	0.36	0.28
EV to sales	0	0	0	0
Enterprise value over EBITDA	-97.55	-22.88	2.41	0.95
EV to operating cash flow	-120.77	-28.04	5.14	1.3
EV to free cash flow	-120.77	-24.45	5.06	1.21
Earnings yield	-0.01	-0.04	-0.82	0
Free cash flow yield	-0.01	-0.04	-0.38	-2.16
Debt to equity	-7.89	-1.65	0.07	0.31
Debt to assets	1.15	2.54	0.07	0.24
Net debt to EBITDA	7.1	0.59	3.65	1.31
Current ratio	26.88	2.2	14.9	5.9
Interest coverage	0	0	0	0
Income quality	0.81	0.79	0.46	0.74
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0
Research and developement to revenue	0	0	0	0
Intangibles to total assets	0	0	0	0
Capex to operating cash flow	0	0.15	0.02	0.07
Capex to revenue	0	0	0	0
Capex to depreciation	0	-3.16	-0.83	-9.03
Stock based compensation to revenue	0	0	0	0
Graham number	0.61	3.06	78.69	0
ROIC	0.14	1.82	0.25	0
Return on tangible assets	-0.14	-1.26	-0.27	0
Graham Net	-0.14	-0.81	30.14	3.9
Working capital	18.97M	4.41M	259.97M	154.98M
Tangible asset value	-2.87M	-15.65M	261.31M	160.82M
Net current asset value	-2.98M	-17.69M	259.97M	136.06M
Invested capital	-0.01	-0.05	0	0.12
Average receivables	0	0	0	0
Average payables	0	784K	6.51M	9.52M
Average inventory	0	0	0	0
Days sales outstanding	0	0	0	0
Days payables outstanding	0	0	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	0	0	0	0
Inventory turnover	0	0	0	0
ROE	0.96	0.82	-0.29	0
Capex per share	0	-0.07	-0.06	-0.19

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-1.85	-0.97	0	-0.85	0
Operating cash flow per share	-0.8	-0.86	-0.73	-0.63	-2.08
Free cash flow per share	-0.81	-0.86	-0.73	-0.76	-2.15
Cash per share	8.66	7.65	6.88	6.1	5.43
Book value per share	8.23	7.23	6.53	5.8	4.87
Tangible book value per share	8.23	7.23	6.53	5.8	4.87
Share holders equity per share	8.23	7.23	6.53	5.8	4.87
Interest debt per share	0.01	0	0.48	0.52	0.57
Market cap	348.12M	130.56M	77.23M	64.15M	44.26M
Enterprise value	73.39M	-116.53M	-130.44M	-118.34M	-116.11M
P/E ratio	-1.48	-1.04	0	-0.58	0
Price to sales ratio	0	0	0	0	0
POCF ratio	-13.71	-4.72	-3.26	-3.12	-0.64
PFCF ratio	-13.5	-4.69	-3.24	-2.58	-0.62
P/B Ratio	1.33	0.56	0.36	0.34	0.28
PTB ratio	1.33	0.56	0.36	0.34	0.28
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-1.26	3.73	5.1	4.42	1.23
EV to operating cash flow	-2.89	4.21	5.5	5.76	1.69
EV to free cash flow	-2.85	4.19	5.47	4.77	1.64
Earnings yield	-0.17	-0.24	0	-0.43	0
Free cash flow yield	-0.07	-0.21	-0.31	-0.39	-1.6
Debt to equity	0.07	0.08	0.14	0.19	0.31
Debt to assets	0.07	0.08	0.13	0.16	0.24
Net debt to EBITDA	4.71	7.92	8.12	6.82	1.7
Current ratio	14.9	13.1	15.19	10.62	5.9
Interest coverage	0	-3.49K	0	-39.49	0
Income quality	0.43	0.88	0.93	0.74	0.74
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0.01	0.01	0.21	0.03
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.83	-0.92	-0.81	-21.33	-4.19
Stock based compensation to revenue	0	0	0	0	0
Graham number	18.5	12.56	0	10.53	0
ROIC	0.06	0.13	0	0.16	0
Return on tangible assets	-0.21	-0.12	0	-0.12	0
Graham Net	8.07	7.05	5.94	5.02	3.9
Working capital	259.97M	232.07M	211.68M	183.71M	154.98M
Tangible asset value	261.31M	233.51M	211.97M	188.75M	160.82M
Net current asset value	259.97M	232.07M	196M	167.66M	136.06M
Invested capital	0	0	0.07	0.09	0.12
Average receivables	0	0	0	0	0
Average payables	6.94M	7M	4.94M	6.66M	6.3M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.22	-0.13	0	-0.15	0
Capex per share	-0.01	0	0	-0.13	-0.06

PYXS Frequently Asked Questions

What is Pyxis Oncology, Inc. stock symbol ?

Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS

What is Pyxis Oncology, Inc. stock quote today ?

Pyxis Oncology, Inc. stock price is $2.21 today.

Is Pyxis Oncology, Inc. stock public?

Yes, Pyxis Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 136.22K
Market Capitalization 91.89M
Employee 73
CEO Dr. Lara S. Sullivan M.D., MBA
Headquarters Cambridge,MA,US
IPO Date 2021-10-08
Website https://www.pyxisoncology.com

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.